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approval. RESULTS: PMW who initiated RLX following the IBCRR approval versus 
before approval were less likely to be in the 50–54 age group compared to all other 
age groups (Adjusted Odds Ratio [AOR] = 1.594 [age 55–59], 1.812 [age 60–64], 
1.667 [age 65–69], 1.782 [age 70+]). RLX initiators were more likely to have a lower 
CDS after the IBCRR approval vs. before approval (medium AOR = 0.795 [Conﬁdence 
Interval (CI): 0.711, 0.889], high AOR = 0.71 [CI: 0.626, 0.805]). After the IBCRR 
approval, RLX initiators had a greater likelihood of having a code for family history 
of BC in the claims database (AOR = 1.761 [CI: 1.213, 2.556]) compared to RLX 
initiators before approval. PMW who initiated RLX after IBCRR approval did not 
differ signiﬁcantly from those who initiated before approval with regard to mam-
mograms, fractures, BMD screening, and provider specialty. CONCLUSIONS: PMW 
who initiated RLX after the IBCRR approval were more likely to be older, have a 
lower CDS, and have a family history of BC compared with RLX initiators before 
approval. Factors such as mammograms, fractures, BMD screening, and provider 
specialty did not differ before and after the IBCRR approval.
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OBJECTIVES: The objective of this study was to evaluate the extent to which oncolo-
gist would participate and comply with a P4Q program employing clinical pathways. 
METHODS: A P4Q program was enacted in ﬁve northeastern states, USA, beginning 
August 1, 2008, and consisted of physician generated treatment (i.e. breast, lung, and 
colon-rectal cancer) and supportive care pathways (i.e. colony-stimulating factors, 
erythropoietin stimulating agents, and antiemetics). Practices were informed of the 
program three months in advance and allowed to sign up for the program prior to 
and during the ﬁrst year of the program. Feedback was provided to participants 
regarding compliance, and increased fee schedules in year 1 were adjusted in year 2 
contingent on compliance in year 1. Compliance was measured through the claims 
submitted by participating practices on cancer patients starting a new line of therapy 
after August 1, 2008. Compliance was deﬁned by provision of a drug or regimen not 
according to the deﬁned pathway. RESULTS: A total of 362 physicians were eligible 
for participation (174 community based; 34 hospital based; 154 academic based). 
49% of all physicians, 88% of community based, 44% of hospital based, and 6% of 
academic physicians signed up to participate in the program. 2,119 cancer patients 
were eligible for compliance analysis. Overall 85.9% of patients were judged compli-
ant to treatment pathways (90.5% breast, 90.9% colon, 72.3% lung). Overall 95.4% 
of patients were compliant to supportive care pathways (100% CSF, 98.6% ESAs, 
91.3% antiemetics). CONCLUSIONS: This study suggests high levels of compliance 
with clinical pathways may be achieved. Participation varied greatly by practice type. 
Additional analysis should consider evaluation of alternate deﬁnitions of compliance 
(e.g. errors of omission rather than commission) and reasons for non-participation 
(e.g. overlap of compliance with potential ﬁnancial advantage of participation).
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OBJECTIVES: Quality of care for cancer may improve with information technology 
products such as ELECTRONIC MEDICAL RECORDS (EMR). The objectives of this 
study were 1) to identify aspects of value of EMR use to providers in assessing and 
improving quality cancer care and 2) to identify issues in cost-effectiveness of EMR 
from the provider perspective. METHODS: A systematic literature review regarding 
perceptions of the quality of cancer care in the United States was conducted in 
PubMed, EMBASE, and Cochrane Reviews for the last 10 years, English only articles. 
Oncology medical subject heading (MESH) terms were cross-matched with quality of 
care MESH terms to obtain 875 abstracts. Of these, 140 publications were selected 
for full-article review based on deﬁned inclusion/exclusion criteria. RESULTS: Reports 
of EMR use among hospitals, hospital networks (for example, Veterans Hospital 
Administration), and moderately sized oncology practices indicated that providers 
rapidly obtained information on guideline adherence and determined whether patients 
received follow-up in physician ofﬁces. Cost savings were incurred across multidisci-
plinary teams because fewer tests were duplicated. Business management costs for 
billing were reduced. Other cost savings were lower labor costs due to reduced need 
for medical records staff, and staff to provide information among caregivers and to 
direct patient ﬂow. Cost effectiveness was variable for small physician practices, with 
some providers recovering the cost of the EMR system and others incurring serious 
ﬁnancial problems as a result of implementing EMR use in their practices. CONCLU-
SIONS: EMR may be ﬁnancially challenging for some small physician practices. 
However, it can assist providers in assessing whether their patients are receiving 
guideline-adherent care and aid in more efﬁcient processes of care, thereby improving 
overall quality of cancer care.
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OBJECTIVES: The oncology market has become one of the major focus areas for 
pharmaceutical and biotech ﬁrms. As of March 2009, 15,752 of 39,747 Phase I,II, 
and III trials listed on clinicaltrials.gov, were related to cancer (approximately 40%). 
This large interest in oncology stems from market success of cancer therapies launched 
in the past decade and the existence of high unmet need to treat different types of 
cancers. As the number of FDA approved cancer therapies increases there is a need 
to understand treatment patterns of these cancer drugs. METHODS: To understand 
the trends in usage and sales of cancer therapies we analyzed the US market (sales and 
prescription) 2005–2008 data for all FDA approved cancer drugs. Drugs were catego-
rized as targeted cancer therapies, chemotherapies, monoclonal antibodies, small 
molecules, branded and generics. RESULTS: During the past ﬁve years the usage of 
both targeted cancer therapies and chemotherapy drugs has increased by high double 
digit rates. From 2005–2008, the total prescriptions for targeted cancer therapies and 
chemotherapies increased by 66% and 30%, respectively. While the sales of both types 
of these drugs are expanding, the majority of sales growth is attributed to an increasing 
uptake of targeted cancer drugs. The sales share of targeted cancer therapies in the 
US oncology market increased from 36% in 2004 to 56% in 2008. Among targeted 
cancer therapies, majority (more than 75%) of uptake belongs to monoclonal antibod-
ies. CONCLUSIONS: The usage and sales trends show a signiﬁcant increase in the 
use of cancer drugs. The high usage of targeted cancer therapies versus chemotherapies 
shows the rapidly changing nature of cancer treatment regimen.
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OBJECTIVES: Systemic chemotherapy is a vital component of breast cancer manage-
ment but early-onset toxicities like neutropenia hinder its administration. Primary 
prophylactic (PP) use of granulocyte-colony stimulating factors (G-CSF) helps prevent 
neutropenia and ensures successful chemotherapy completion. Nevertheless, lack of 
speciﬁc guidelines for G-CSF administration in the elderly has lead to unexplained 
geographic and racial, and counter-intuitive clinical variations. For example, older 
individuals with higher co-morbidities (at higher neutropenia risk) have lower prob-
ability of G-CSF receipt. This study examined the reasons for these variations and for 
the ﬁrst time looked at variations in PP administration in breast cancer patients. 
METHODS: A retrospective observational study of newly diagnosed breast cancer 
patients receiving chemotherapy was performed using the 1994–2003 SEER-Medicare 
data. Univariate analyses and multi-variate logistic regressions were used to explore 
the determinants of PPG-CSF administration. Previously unexplored clinical and 
therapeutic characteristics (e.g. chemotherapy characteristics before the administration 
of PPG-CSF) were also included. RESULTS: Univariate analyses demonstrated geo-
graphic, racial and clinical disparities similar to previous studies. However, multi-
variate analyses revealed that controlling for chemotherapy characteristics (type and 
number of drugs and between cycle duration) made the correlation of age and other 
clinical characteristics with PPG-CSF administration insigniﬁcant. Signiﬁcant geo-
graphic and racial disparities existed. Exploration of geographic variations suggested 
that regions with higher rates of PPG-CSF administration have higher proportion of 
physicians administering them; none of the physicians using PPG-CSF administered it 
on a signiﬁcantly higher proportion of their patients. CONCLUSIONS: Physicians’ 
decision to administer PPG-CSF is predominantly driven by neutropenia risk associ-
ated with pre-planned chemotherapy regimen. Older, sicker women at a higher risk 
of neutropenia received less intense/toxic chemotherapy thus did not require PPG-CSF. 
Geographic variations are driven by provider-level variations in PPG-CSF administra-
tion with no evidence for overuse among the providers. Racial and geographic dispari-
ties have no clinical basis and are a matter of concern.
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OBJECTIVES: To examine the prescribing patterns of the recommended pharmaco-
logic treatments for metastatic renal cell carcinoma (mRCC). METHODS: A retrospec-
tive claims-based analysis was conducted that identiﬁed incident mRCC patients 
(18–64 years) in the Thomson Reuters MarketScan Commercial Claims Database 
(January 2005–September 2008). Patients were required to have at least 6 months of 
continuous enrollment before the index date (ﬁrst metastases claim) and at least 30 days 
of continuous enrollment after the index date. Treatment patterns were described as 
proportions of mRCC patients receiving the following guideline-recommended phar-
macologic agents: immunotherapies (interferon-alpha and interleukin-2) and the newer 
targeted agents (sunitinib, sorafenib, bevacizumab, temsirolimus and everolimus), 
either as initial or second-line therapies any time on or after the index date. RESULTS: 
A total of 1390 patients with mRCC were included in the analysis. Mean age was 55.6 
years and 70.5% were male. The mean continuous enrollment after diagnosis of metas-
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tasis was 10.9 ± 8.9 months. The percentages of patients receiving at least one of these 
therapies increased from 10.5% in 2005 to 74% in 2008. Sunitinib use showed consis-
tent increase from 0% in 2005 to 50% in 2008. Sorafenib with zero use in 2005 
increased to 25% in 2006 but decreased thereafter to 11.7% in 2008. Interferon-alpha 
(range: 5–8%) and bevacizumab (range: 2–4%) use remained relatively stable during 
the observation period, whereas interleukin-2 and temsirolimus was used rarely (≤1%) 
and everolimus not used at all. CONCLUSIONS: Pharmacologic agents were increas-
ingly used to treat mRCC patients in recent years. Targeted therapies have become the 
main modality of treatment, with sunitinib accounting for most of the growth.
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OBJECTIVES: There is no evidence about real medical practice in oncology in 
Mexico. The objective of this study was to explore current medical practices of 
Mexican oncologists in the management of ﬁve malignancies: breast, non-small cell 
lung (NSCL), colon, rectum and kidney cancer. METHODS: A speciﬁc instrument for 
these malignancies was designed, validated and applied to Mexican oncologists. Infor-
mation requested reﬂects stage-speciﬁc treatment and disease management, including 
surgery and drugs uses, as well as frequency of prescription, discontinuation and 
factors that determines them in public and private health care institutions, between 
January-April 2009. RESULTS: 30 oncologists were included: 63.3% from Instituto 
Mexicano del Seguro Social and 20.0% from Instituto Nacional de Cancerología. 
73.3% of all oncologists have public and private practices. Tamoxiphen (adjuvant 
hormonoterapy) and 5-ﬂuoroacil/epirubicin/cyclophosphamide (adjuvant, neoadju-
vant and palliative chemotherapy) are the most frequently drug schemes used in breast 
cancer, with no differences between public and private practices(p < 0.05). At least 
85.0% of NSCL cancer cases are diagnosed in IIIA and IV stages; combination che-
motherapy (platinum/etoposide) is highly prescribed in NSCL cancer patients undergo-
ing radiotherapy or non-resectable disease. Colon cancer is diagnosed in stages 
III(58.0%) and IV (14.0%); 20.0% of colon cancer patients undergoes surgery (left 
or right hemicolectomy). Drug availability and medical guidelines recommendations 
drive prescription to treat colon cancer. Surgery in rectum cancer is applied at stages 
IIB, IIIA and IIIB (17.6%, 20.0% and 16.9%, respectively). Rectum cancer presents 
as non-resectable disease in 60.0% of cases in stage IV. Drugs used to treat metastatic 
renal cells cancer are interferon-α (80.0%) and sunitinib(19.0%), prescription is 
driven by drug availability and efﬁcacy, respectively. Discontinuation rate of inter-
feron-α due adverse event was 90.0%. CONCLUSIONS: Knowledge of oncology 
current medical practice provides a basis for evaluation, as well as supports decision 
making process and the generation of new strategies for policy makers.
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OBJECTIVES: Colorectal cancer (CRC) is the third most common form of cancer in 
men and women in West Virginia. Hospitalization followed by surgical resection is 
the standard curative treatment. The aim of this study is to examine colorectal cancer 
hospitalizations and common comorbidities and evaluate associated outcomes during 
2003–2007 in West Virginia. METHODS: Data from the Healthcare Cost and Utiliza-
tion Project (HCUP), State Inpatient Database were investigated. Comorbidities were 
identiﬁed using comorbidity software provided by HCUP. Descriptive statistics for 
hospitalizations with a primary or secondary diagnosis of CRC were tabulated. Mul-
tivariate regressions were used to compare for differences in the outcomes including 
length of stay, total charges, and in-hospital deaths. RESULTS: There were 6919 
admissions with a primary or secondary diagnosis of CRC of which 27.4% were 
emergency admissions. The most common comorbidity was diabetes (18.5%), fol-
lowed by COPD and hypertension (both 3.7%). Volume depletion disorder (3.5%) 
followed by pneumonia (2.4%) and malignant neoplasm of the liver (2.3%) were the 
most common primary diagnoses seen when CRC was the secondary diagnosis. Mean 
length of stay was signiﬁcantly higher for admissions with a primary diagnosis (9.2 
days versus 4.8 days, p < 0.001). Mean total charges were also higher for primary 
diagnosis (28,618.94 USD versus 12,195.22 USD, p < 0.001). For the 356 (5.1%) 
in-hospital deaths, emergency admissions had odds ratio (OR) of 2.50 (95% CI, 
2.01–3.10), and primary diagnosis of CRC had OR of 1.64 (95% CI, 1.30–2.08). 
Admissions with comorbid diabetes formed 12.6% (45) of patients who died in the 
hospital. CONCLUSIONS: Signiﬁcant resources are consumed by CRC hospital 
admissions. A large percentage of CRC hospitalizations are emergency admissions 
indicating advanced disease and possibly failure of timely screening. Diabetes was the 
most common comorbid condition and further investigation in diabetics is needed to 
check screening behavior and access to screening centers.
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OBJECTIVES: Triple negative (TN) breast cancer (BC), a subtype of BC characterized 
by its unique molecular proﬁle and aggressive clinical behavior, lacks satisfactory 
standard therapies. Little is known about how patients with TNBC were treated in 
community practice. This study was conducted to identify treatment patterns of ﬁrst-
line chemotherapy (CT) of TNBC using data from community practices. METHODS: 
Analyses were conducted using the Georgia Cancer Specialist Database (GCSD 2003–
2008) and the International Oncology Network’s Treatment and Outcomes Database 
(ION 2003–2008). In both data, patients with stage IV TNBC were selected and fol-
lowed for up to one year since initial diagnosis. The ﬁrst-line CT was identiﬁed if 1) 
the ﬁrst drug was initiated within 120 days following the initial BC diagnosis; 2) other 
combination drugs be started within 30 days of the ﬁrst drug. RESULTS: The study 
included 30 and 35 patients from GCSD and ION, respectively. In GCSD sample, 14 
patients (47%) were treated with monotherapy, capecitabine and taxanes being domi-
nant (50% and 43%, respectively); 16 patients treated with combination therapy, with 
carboplatin/gemcitabine+paclitaxel (C/G+P) and cyclophosphomide+doxorubicin 
(CP+DOX) most frequently used regimens or backbone therapies (31% for each). 
Other drugs used in combination included docetaxel, bevacizumab, 5-FU and albu-
min-bound P. Similar patterns were found in ION sample with some deviations: 20 
patients (57%) treated with monotherapy, taxanes being dominant (70%); 15 patients 
treated with combination therapy, C/G+P and CP+DOX/+epirubicin were the most 
frequently used regimens or backbone therapies (33% for each). Other drugs used in 
combination included docetaxel, 5-FU, bevacizumab, lapatinib and methotrexate. 
CONCLUSIONS: It appears that taxanes/capecitabine, and C/G+P or CP+DOX were 
mostly used monotherapy and combination therapy, respectively, for stage IV TNBC. 
The patterns are rather diverse than convergent, reﬂecting lack of standard therapy 
for TNBC. Data from other community settings are needed to conﬁrm these results.
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BACKGROUND: Ascertainment of vital status is critical to studies in many disease 
areas especially in oncology. Two commonly used sources for mortality are SSDMF 
and NDI, with NDI considered the gold standard. Limitations identiﬁed in previous 
studies are under-ascertainment associated with the former; time lag (1–2 years) and 
higher cost associated with the latter. OBJECTIVES: To compare ascertainment of 
vital status by consolidating mortality data from SSDMF and NDI vs. either source 
alone. METHODS: Patient identiﬁers for a cohort of 3761 cancer patients from a 
large US claims database were submitted to SSDMF (cutoff February 2009) and NDI 
(cutoff December 2007) to obtain vital status. Matching to SSDMF utilized SSN alone 
or a combination of last name, ﬁrst name and birthdate. Matching to NDI utilized 
combinations of SSN and/or patient name, birthdate, and state of residence. For 
patients with a death date found in NDI, a variable indicating a true or false match 
was provided by NDI based on the probabilistic score. We derived the death date via 
a stepwise approach by utilizing all match results from either source. RESULTS: Of 
3761 patients, SSDMF returned a match for 901 (24%) patients using SSN alone, and 
1088 (29%) patients using the combination. From the NDI, 946 (25%) patients had 
a “true” match, 1408 (37%) had a “false” match, and remainder were considered 
alive. Comparing SSDMF and NDI results utilizing both true and false NDI matches, 
we derived death dates for 1326 patients, which is 47% and 40% more compared to 
SSDMF match by SSN alone or NDI true match, respectively. Eight patients had claims 
following death date and were considered false matches. CONCLUSIONS: Utilizing 
all match results from SSDMF and NDI identiﬁed signiﬁcantly more deceased patients 
compared to either source alone. Misclassiﬁcation of living patients as deceased 
appears minimal as veriﬁed by claims.
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Febrile neutropenia (FN) is a condition that develops in cancer patients treated with 
myelosuppressive chemotherapy characterized by fever and very low neutrophil 
counts, in general signaling infection. Utilizing claims data can provide a real-world 
perspective on the epidemiology, treatment, outcomes, and costs associated with FN 
in cancer patients. However, identifying true cases of FN in claims data can be prob-
